ATE114479T1 - Über thioetherbindungen verknüpfte immunokonjugate, mit verminderter toxizität und vermehrter selektivität. - Google Patents
Über thioetherbindungen verknüpfte immunokonjugate, mit verminderter toxizität und vermehrter selektivität.Info
- Publication number
- ATE114479T1 ATE114479T1 AT88114682T AT88114682T ATE114479T1 AT E114479 T1 ATE114479 T1 AT E114479T1 AT 88114682 T AT88114682 T AT 88114682T AT 88114682 T AT88114682 T AT 88114682T AT E114479 T1 ATE114479 T1 AT E114479T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- toxin
- group
- forming
- derivatized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/095,178 US4981979A (en) | 1987-09-10 | 1987-09-10 | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE114479T1 true ATE114479T1 (de) | 1994-12-15 |
Family
ID=22250495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT88114682T ATE114479T1 (de) | 1987-09-10 | 1988-09-08 | Über thioetherbindungen verknüpfte immunokonjugate, mit verminderter toxizität und vermehrter selektivität. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4981979A (de) |
| EP (1) | EP0306943B1 (de) |
| JP (1) | JPH01163132A (de) |
| AT (1) | ATE114479T1 (de) |
| AU (1) | AU622415B2 (de) |
| CA (1) | CA1336496C (de) |
| DE (1) | DE3852250T2 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
| US5792458A (en) * | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5208021A (en) * | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| US5352447A (en) * | 1987-10-05 | 1994-10-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy |
| FI102355B1 (fi) * | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5112954A (en) * | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
| US5024834A (en) * | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
| US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
| NL8802458A (nl) * | 1988-10-07 | 1990-05-01 | Philips Nv | Werkwijze voor de vervaardiging van een epitaxiale indiumfosfide-laag op een substraatoppervlak. |
| DE3900649A1 (de) * | 1989-01-11 | 1990-07-12 | Boehringer Mannheim Gmbh | Verfahren zur abloesung eines analyten von seinem bindeprotein |
| US5354554A (en) * | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
| US5714149A (en) * | 1989-02-10 | 1998-02-03 | Celltech Therapeutics Limited | Crosslinked antibodies and processes for their preparation |
| CA2015938C (en) * | 1989-05-02 | 1999-09-07 | Kevin M. Knigge | Covalent attachment of specific binding members to a solid phase |
| GB8927365D0 (en) * | 1989-12-04 | 1990-01-31 | Ici Plc | Reagent |
| SE9002479D0 (sv) * | 1990-07-20 | 1990-07-20 | Pharmacia Ab | Antibody conjugates |
| ES2094231T3 (es) * | 1990-07-20 | 1997-01-16 | Pharmacia & Upjohn Ab | Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion. |
| US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
| US5725857A (en) * | 1991-02-11 | 1998-03-10 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in vivo T cell suppressant activity and methods of use |
| US5167956A (en) * | 1991-02-11 | 1992-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in-vivo t cell suppressant activity |
| ATE177841T1 (de) * | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
| US6777190B1 (en) | 1991-04-10 | 2004-08-17 | Biosite, Inc. | Crosstalk inhibitors and their uses |
| US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| WO1994016729A1 (en) * | 1993-01-28 | 1994-08-04 | Neorx Corporation | Targeted nitric oxide pathway or nitric oxide synthase modulation |
| US5648218A (en) * | 1993-02-12 | 1997-07-15 | Sealite Sciences, Inc. | Preparation of photoprotein conjugates and methods of use thereof |
| WO1994018342A1 (en) * | 1993-02-12 | 1994-08-18 | Sealite Sciences, Inc. | Preparation of photoprotein conjugates and methods of use thereof |
| KR100361933B1 (ko) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
| US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| US6342389B1 (en) | 1995-04-10 | 2002-01-29 | Roger S. Cubicciotti | Modified phycobilisomes and uses therefore |
| US6632928B1 (en) | 1997-03-05 | 2003-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxins and methods of inducing immune tolerance |
| US7288254B2 (en) | 1995-10-30 | 2007-10-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| US7517527B2 (en) | 1995-10-30 | 2009-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in vivo T cell suppressant activity and methods of use |
| US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| EP0871490B1 (de) * | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Verzweigte hydrazongruppen enthaltende kuppler |
| DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
| ATE218892T1 (de) * | 1997-11-07 | 2002-06-15 | Conjuchem Inc | Affinitätsmarkierer für menschliches serum albumin |
| US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| WO2001054731A2 (en) * | 2000-01-28 | 2001-08-02 | National University Of Singapore | Ligand conjugates and methods for preparing same |
| US20010051348A1 (en) | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CA2414076A1 (en) * | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| GB0020717D0 (en) * | 2000-08-22 | 2000-10-11 | Smithkline Beecham Biolog | Novel compounds and process |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| JP4959136B2 (ja) | 2002-12-13 | 2012-06-20 | イミューノメディクス、インコーポレイテッド | 細胞内で開裂可能な結合を有する免疫接合体 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7736644B2 (en) * | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| EP3243527B1 (de) | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunkonjugate mit einem intrazellulär spaltbaren linker |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| WO2012054717A2 (en) * | 2010-10-21 | 2012-04-26 | The Johns Hopkins University | Detecting and treating solid tumors through selective disruption of tumor vasculature |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| AU2013360335B2 (en) | 2012-12-13 | 2017-12-07 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US20240148873A1 (en) | 2012-12-13 | 2024-05-09 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| WO2017139623A1 (en) | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
| EP3448260A4 (de) | 2016-04-27 | 2019-10-09 | Immunomedics, Inc. | Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren |
| WO2018158716A1 (en) | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
| US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| CN116754760B (zh) * | 2023-06-14 | 2024-01-26 | 之江实验室 | 2,4-二硝基苯酚(dnp)与抗体可控断裂偶联的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
| FR2516794B1 (fr) * | 1981-11-20 | 1985-10-25 | Sanofi Sa | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
| US4429008B1 (en) * | 1981-12-10 | 1995-05-16 | Univ California | Thiol reactive liposomes |
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
| US4434236A (en) * | 1982-10-20 | 1984-02-28 | E. I. Du Pont De Nemours & Co. | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue |
| JPS59116229A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| EP0158291A3 (de) * | 1984-04-10 | 1988-07-27 | Takeda Chemical Industries, Ltd. | Verfahren zur Reinigung von karzinoembryonischem Antigen und Verfahren zur Herstellung eines monoklonalen Antikörpers, der mit karzinoembryonischem Antigen reagiert |
| CA1283661C (en) * | 1984-06-20 | 1991-04-30 | Franz Jansen | Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4657853A (en) * | 1984-09-14 | 1987-04-14 | E. I. Du Pont De Nemours And Company | Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody |
| US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
| US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| US4680338A (en) * | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4911911A (en) * | 1985-12-20 | 1990-03-27 | Sanofi | Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein |
-
1987
- 1987-09-10 US US07/095,178 patent/US4981979A/en not_active Expired - Lifetime
-
1988
- 1988-09-08 EP EP88114682A patent/EP0306943B1/de not_active Expired - Lifetime
- 1988-09-08 AT AT88114682T patent/ATE114479T1/de active
- 1988-09-08 DE DE3852250T patent/DE3852250T2/de not_active Expired - Fee Related
- 1988-09-09 CA CA000576911A patent/CA1336496C/en not_active Expired - Fee Related
- 1988-09-09 AU AU22095/88A patent/AU622415B2/en not_active Ceased
- 1988-09-10 JP JP63225564A patent/JPH01163132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US4981979A (en) | 1991-01-01 |
| CA1336496C (en) | 1995-08-01 |
| EP0306943A3 (en) | 1989-11-15 |
| JPH01163132A (ja) | 1989-06-27 |
| AU622415B2 (en) | 1992-04-09 |
| AU2209588A (en) | 1989-03-16 |
| EP0306943A2 (de) | 1989-03-15 |
| DE3852250D1 (de) | 1995-01-12 |
| EP0306943B1 (de) | 1994-11-30 |
| DE3852250T2 (de) | 1995-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3852250D1 (de) | Über Thioetherbindungen verknüpfte Immunokonjugate, mit verminderter Toxizität und vermehrter Selektivität. | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| DK439885D0 (da) | Baeremateriale til anvendelse ved immunbestemmelser | |
| DE68911397D1 (de) | Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen. | |
| DE68921982D1 (de) | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. | |
| ES520692A0 (es) | Un procedimiento de preparacion de conjugados inmunoenzimaticos. | |
| RO82758A (ro) | Procedeu de preparare a unor imunoglobulinei conjugate | |
| US4797491A (en) | Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane | |
| GR3025630T3 (en) | Monoclonal antibody against human IgE | |
| PT85317A (fr) | Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine | |
| BR9303898A (pt) | Processo para preparar um conjugado imunogênico de isotiazolonas e veículo macromolecular, para produzir anticorpos monoclonais e para determinar a presença ou concentraçao de isotiazolonas e composiçao compreendendo um hibridoma | |
| DK0585570T3 (da) | Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse | |
| YU46858B (sh) | Postupak za dobijanje imunoglobulinskih konjugata | |
| DE3850993D1 (de) | Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2. | |
| EP0338395A3 (en) | Monoclonal antibodies to pseudomonas aeruginosa, their production and use | |
| KR890701130A (ko) | 안지오제닌(Angiogenin)에 대한 항체 : 면역제 | |
| DE3579808D1 (de) | Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung. | |
| ATE83930T1 (de) | Antikoerper enthaltende stabilisierte waesserige zusammensetzung. | |
| ATE86261T1 (de) | Tumorassoziiertes antigen. | |
| SE8704114D0 (sv) | Monoclonal antibody, a process for its preparation and the use thereof | |
| KR850008344A (ko) | 일가의 카르복실 이오노포르와 거대분자가 공유결합에 의해 결합된 접합체의 제조방법 | |
| ATE92081T1 (de) | Tumorassoziiertes antigen. | |
| DE69925009D1 (de) | Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren | |
| SE8702911D0 (sv) | Plektrum for strenginstrument | |
| FI102217B1 (fi) | Menetelmä Pseudomonas aeruginosa-serotyyppien toteamiseksi näytteestä in vitro monoklonaalisten vasta-aineiden avulla, menetelmässä käytettäviä monoklonaalisia vasta-aineita sekä menetelmässä käyttökelpoinen testipakkaus |